All In Biotech

Drug Trial Radar · NCT03567291

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

228

Actual

Start

May 25, 2018

Primary completion

May 15, 2020

Study completion May 15, 2020

Sponsor

Sponsor type
Industry
Collaborators
Nuvelution TS Pharma, Inc.
First posted
Jun 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an otherwise open-label, single-arm study that includes a 2-week, double-blind, placebo controlled, randomized drug withdrawal period followed by a 3 week blinded maintenance or re-titration, and then a maintenance period. This study aims to evaluate the safety and efficacy of TEV-50717 tablets in patients with tics associated with TS who have previously completed participation in any of the parent studies.

Conditions

  • Tourette Syndrome

Interventions

  • TEV-50717Drug

    6, 9, and 12 mg oral tablets

  • PlaceboDrug

    Placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Treatment Emergent Adverse Events (AEs) for Parts A & B CombinedTime frame: Day 1 to Week 55
  2. Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II)Time frame: Weeks 28 to 30
  3. Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total ScoreTime frame: Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
  4. Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total ScoreTime frame: Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
  5. Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score at Week 30Time frame: Week 28, Week 30
  6. Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total Score at Week 30Time frame: Week 28, Week 30
  7. Number of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
  8. Number of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS) at Randomized Withdrawal Baseline Visit (Week 28) and Week 30Time frame: Week 28, Week 30

Locations

76 sites in 15 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 046-0104

    Dothan, Alabama

  • Teva Investigational Site 046-0107

    Rogers, Arkansas

  • Teva Investigational Site 046-0126

    Anaheim, California

  • Teva Investigational Site 046-0101

    Sacramento, California

  • Teva Investigational Site 046-0111

    San Diego, California

  • Teva Investigational Site 060-0160

    Gainesville, Florida

  • Teva Investigational Site 060-0166

    Gulf Breeze, Florida

  • Teva Investigational Site 060-0161

    Miami, Florida

  • Teva Investigational Site 046-0115

    Orlando, Florida

  • Teva Investigational Site 060-0153

    Orlando, Florida

  • Teva Investigational Site 046-0114

    St. Petersburg, Florida

  • Teva Investigational Site 046-0116

    Atlanta, Georgia

  • Teva Investigational Site 060-0155

    Chicago, Illinois

  • Teva Investigational Site 060-0164

    Chicago, Illinois

  • Teva Investigational Site 046-0133

    Naperville, Illinois

  • Teva Investigational Site 046-0128

    Boston, Massachusetts

  • Teva Investigational Site 060-0170

    Bridgeton, Missouri

  • Teva Investigational Site 046-0110

    Saint Charles, Missouri

  • Teva Investigational Site 046-0134

    Lincoln, Nebraska

  • Teva Investigational Site 046-0109

    Voorhees Township, New Jersey

  • Teva Investigational Site 046-0124

    New York, New York

  • Teva Investigational Site 060-0154

    New York, New York

  • Teva Investigational Site 046-0102

    Rochester, New York

  • Teva Investigational Site 046-0106

    Oklahoma City, Oklahoma

  • Teva Investigational Site 060-0169

    Charleston, South Carolina

  • Teva Investigational Site 060-0156

    Nashville, Tennessee

  • Teva Investigational Site 046-0113

    Dallas, Texas

  • Teva Investigational Site 060-0163

    Fort Worth, Texas

  • Teva Investigational Site 046-0108

    Houston, Texas

  • Teva Investigational Site 046-0120

    San Antonio, Texas

  • Teva Investigational Site 046-0105

    Orem, Utah

  • Teva Investigational Site 046-0118

    Petersburg, Virginia

  • Teva Investigational Site 060-0162

    Everett, Washington

  • Teva Investigational Site 060-1407

    Buenos Aires, Argentina

  • Teva Investigational Site 060-1402

    Buenos Aires, Argentina

  • Teva Investigational Site 060-1403

    La Plata, Argentina

  • Teva Investigational Site 060-1404

    Mendoza, Argentina

  • Teva Investigational Site 060-1802

    Liverpool, Australia

  • Teva Investigational Site 046-0201

    Ajax, Ontario, Canada

  • Teva Investigational Site 046-0202

    Ottawa, Ontario, Canada

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.